悦康药业：子公司YKYY032注射液获得国家药品监督管理局和FDA临床试验批准

Core Viewpoint - Yuyuan Pharmaceutical announced that its subsidiaries, Beijing Yuyuan Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd., have recently received approval from the National Medical Products Administration for the clinical trial of YKYY032 injection for the treatment of hyperlipoproteinemia(a) [1] Group 1 - Yuyuan Kechuang has also received a notification from the U.S. Food and Drug Administration (FDA) granting permission to conduct clinical trials for YKYY032 injection for the treatment of hyperlipoproteinemia(a) [1]